Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Robots make it to the healthcare conference panel, reflecting the future potential of technology
Sets price band at ?695 to ?735 per Equity Share
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
The three-week travel campaign is aimed at spreading awareness about infertility and making Karnataka infertility-free
Subscribe To Our Newsletter & Stay Updated